ICU fungus study aims to uncover resistance secrets
NCT ID NCT07245563
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will look at Candida fungi from 300 patients in a hematology ICU. Researchers want to see how often these fungi form biofilms (slimy layers that protect them) and whether that makes them resistant to antifungal drugs. The goal is to learn which Candida types are most common and what factors lead to harder-to-treat infections.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors choose better antifungal treatments for ICU patients with Candida infections.
- What could go wrong
- This is an observational study, not testing a new treatment. It may not directly change patient care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 300 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Dec 2025
An estimate. Start dates often move.
- Expected to finish
-
Oct 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
patients admitted to hematology intensive care
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Eligible participants in the study were those with invasive infection and had one or more of this criteria : oSuppressed general body immunity. oSuppressed local body immunity as a result of trauma or invasive procedures. oResistant to antibiotic therapy. oNegative samples for bacterial examination and culture. Critical life threatening infect Exclusion Criteria: * Patients who received antifungal therapy within 3 days prior to sample collection. * Resistant to antibiotic therapy.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Candida infection are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Once-a-Week IV antifungal tested against daily standard for dangerous candida infections
- Can a 10-Day antifungal course beat the standard 14 days?
- Can a quick PCR test speed up lifesaving fungal infection diagnosis?
- Baby thrush may predict cavity risk: study investigates link
- Blood biomarkers may let ICU patients stop antifungals earlier
- Could 7 days of antifungals be enough for kids with blood infections?